10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The expression signature of very long non-coding RNA in myalgic encephalomyelitis/chronic fatigue syndrome

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic debilitating disease with huge social-economic impact. It has been suggested that immune dysregulation, nitrooxidative stress, and metabolic impairment might contribute to disease pathogenesis. However, the etiology of ME/CFS remains largely unclear, and diagnostic/prognostic disease markers are lacking. Several long noncoding RNAs (lncRNA, > 200 bp) have been reported to play roles in immunological diseases or in stress responses.

          Methods

          In our study, we examined the expression signature of 10 very long lncRNAs (> 5 kb, CR933609, His-RNA, AK124742, GNAS1-AS, EmX2OS, MIAT, TUG1, NEAT1, MALAT1, NTT) in the peripheral blood mononuclear cells of 44 ME/CFS patients.

          Results

          LncRNAs NTT, MIAT and EmX2OS levels were found to be significantly elevated in ME/CFS patients as compared with healthy controls. Furthermore, NTT and EmX2OS levels increased with disease severity. Stimulation of human monocytic cell line THP-1 and glioma cell line KALS1 with H 2O 2 (oxidative stress) and poly (I:C) (double strand RNA, representing viral activation) increased the expression levels of NTT and MIAT.

          Conclusions

          Our study revealed a ME/CFS-associated very long lncRNA expression signature, which might reflect the regulatory response in ME/CFS patients to oxidative stress, chronic viral infection and hypoxemia. Further investigations need to be done to uncover the functions and potential diagnostic value of these lncRNAs in ME/CFS.

          Related collections

          Most cited references30

          • Record: found
          • Abstract: found
          • Article: not found

          lncRNA-MIAT regulates microvascular dysfunction by functioning as a competing endogenous RNA.

          Pathological angiogenesis is a critical component of diseases, such as ocular disorders, cancers, and atherosclerosis. It is usually caused by the abnormal activity of biological processes, such as cell proliferation, cell motility, immune, or inflammation response. Long noncoding RNAs (lncRNAs) have emerged as critical regulators of these biological processes. However, the role of lncRNA in diabetes mellitus-induced microvascular dysfunction is largely unknown.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Metabolic features of chronic fatigue syndrome.

            More than 2 million people in the United States have myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). We performed targeted, broad-spectrum metabolomics to gain insights into the biology of CFS. We studied a total of 84 subjects using these methods. Forty-five subjects (n = 22 men and 23 women) met diagnostic criteria for ME/CFS by Institute of Medicine, Canadian, and Fukuda criteria. Thirty-nine subjects (n = 18 men and 21 women) were age- and sex-matched normal controls. Males with CFS were 53 (±2.8) y old (mean ± SEM; range, 21-67 y). Females were 52 (±2.5) y old (range, 20-67 y). The Karnofsky performance scores were 62 (±3.2) for males and 54 (±3.3) for females. We targeted 612 metabolites in plasma from 63 biochemical pathways by hydrophilic interaction liquid chromatography, electrospray ionization, and tandem mass spectrometry in a single-injection method. Patients with CFS showed abnormalities in 20 metabolic pathways. Eighty percent of the diagnostic metabolites were decreased, consistent with a hypometabolic syndrome. Pathway abnormalities included sphingolipid, phospholipid, purine, cholesterol, microbiome, pyrroline-5-carboxylate, riboflavin, branch chain amino acid, peroxisomal, and mitochondrial metabolism. Area under the receiver operator characteristic curve analysis showed diagnostic accuracies of 94% [95% confidence interval (CI), 84-100%] in males using eight metabolites and 96% (95% CI, 86-100%) in females using 13 metabolites. Our data show that despite the heterogeneity of factors leading to CFS, the cellular metabolic response in patients was homogeneous, statistically robust, and chemically similar to the evolutionarily conserved persistence response to environmental stress known as dauer.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found
              Is Open Access

              Myalgic Encephalomyelitis/Chronic Fatigue Syndrome – Evidence for an autoimmune disease

              Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a frequent and severe chronic disease drastically impairing life quality. The underlying pathomechanism is incompletely understood yet but there is convincing evidence that in at least a subset of patients ME/CFS has an autoimmune etiology. In this review, we will discuss current autoimmune aspects for ME/CFS. Immune dysregulation in ME/CFS has been frequently described including changes in cytokine profiles and immunoglobulin levels, T- and B-cell phenotype and a decrease of natural killer cell cytotoxicity. Moreover, autoantibodies against various antigens including neurotransmitter receptors have been recently identified in ME/CFS individuals by several groups. Consistently, clinical trials from Norway have shown that B-cell depletion with rituximab results in clinical benefits in about half of ME/CFS patients. Furthermore, recent studies have provided evidence for severe metabolic disturbances presumably mediated by serum autoantibodies in ME/CFS. Therefore, further efforts are required to delineate the role of autoantibodies in the onset and pathomechanisms of ME/CFS in order to better understand and properly treat this disease.
                Bookmark

                Author and article information

                Contributors
                886-4-22052121 , yangginan81@gmail.com
                sandra.bauer@charite.de
                tw.lesswind@gmail.com
                franziska.sotzny@charite.de
                d6781@mail.cmuh.org.tw
                carmen.scheibenbogen@charite.de
                Journal
                J Transl Med
                J Transl Med
                Journal of Translational Medicine
                BioMed Central (London )
                1479-5876
                17 August 2018
                17 August 2018
                2018
                : 16
                : 231
                Affiliations
                [1 ]ISNI 0000 0004 0572 9415, GRID grid.411508.9, Department of Laboratory Medicine, , China Medical University Hospital, ; Taichung, Taiwan
                [2 ]ISNI 0000 0001 0083 6092, GRID grid.254145.3, Division of General Pediatrics, , Children’s Hospital of China Medical University, ; Taichung, Taiwan
                [3 ]ISNI 0000 0001 0083 6092, GRID grid.254145.3, College of Medicine, , China Medical University, ; Taichung, Taiwan
                [4 ]ISNI 0000 0004 0572 9415, GRID grid.411508.9, Center for Precision Medicine, , China Medical University Hospital, ; Taichung, Taiwan
                [5 ]ISNI 0000 0001 2218 4662, GRID grid.6363.0, Institute for Medical Immunology, , Charité-Universitätsmedizin Berlin, ; Augustenburger Platz 1, 13353 Berlin, Germany
                Author information
                http://orcid.org/0000-0003-2516-5904
                Article
                1600
                10.1186/s12967-018-1600-x
                6098652
                30119681
                5d82103b-ab34-4c0d-9b2d-2325426c26cf
                © The Author(s) 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 14 June 2018
                : 3 August 2018
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100004663, Ministry of Science and Technology, Taiwan;
                Award ID: 106-2314-B-039-047-MY3
                Award Recipient :
                Funded by: the Lost Voices Foundation e.V., Germany
                Categories
                Research
                Custom metadata
                © The Author(s) 2018

                Medicine
                myalgic encephalomyelitis/chronic fatigue syndrome,long non-coding rna,expression signature,peripheral blood mononuclear cells

                Comments

                Comment on this article